$Inventiva (IVA.US)$ Inventiva (NASDAQ:[Share Link: IVA]) re...
$Inventiva(IVA.US$ Inventiva (NASDAQ:IVA) reported a Phase 2 study of its drug candidate lanifibranor met its primary efficacy endpoint in the treatment of patients with MASH/NASH and type 2 diabetes.
Disclaimer: Community is offered by Moomoo Technologies Inc. and is for educational purposes only.
Read more
Comment
Sign in to post a comment